Clinical Practice Guidelines (CPG)
Cardiovascular diseases are undoubtedly the leading cause of death worldwide and certainly in Malaysia. In dealing with the increasing cardiovascular disease burden, it is paramount that contemporary clinical cardiology practice mirrors the ever-growing scientific medical knowledge. Cardiac magnetic resonance (CMR) being the latest addition to the clinical armamentarium of cardiovascular imaging is certainly no different. The importance of CMR is such that today it has already become the gold standard clinical test in some cardiac diseases.
Cardiovascular disease remains the world'd biggest killer with coronary artery disease (CAD) being the largest contributor. In Malaysia, it has surpassed infective diseases as the leading cause of death, making it the most important non-communicable disease that the nation has to combat against. Cardiac computed tomography (CCT) has been utilised in the last 20 years as one of the imaging modality used to diagnose CAD. Its tremendous growth in technology has seen its application grow from coronary calcium imaging and noninvasive coronary angiography to more functional cardiac and non-coronary work. With these advancements, Malaysia has to keep abreast with the contemporary use and application of this modality to be in parallel with the rest of the world.
This Appropriate Use Criteria (AUC) has been developed to serve as a supplement to the Clinical Practice Guideline (CPG). It does not replace the CPGs which are evidence based. The objective of the AUC document is to combine the best available scientific evidence with the collective judgement of experts to produce a statement regarding the appropriateness of performing procedure at the level of patient specific symptoms, medical history and test results. The aim is not to reflect the number of procedures being performed but to ensure that these are done appropriately based on current evidence.
Clinical Practice Guidelines- Management Of Acute ST Segment Elevation Myocardial Infarction (STEMI) 2014 - (3rd edition)
ST segment myocardial infarction (STEMI) is the most deadly among the clinical presentations of acute coronary syndrome (ACS). Unlike many medical conditions, STEMI is associated with high mortality and morbidity in its early stages, including sudden death. The National Cardiovascular Disease (NCVD) ACS Registry revealed that there was a 10% mortality for patients who were admitted to hospital with STEMI in 2006-2008.
- Coronary artery disease (CAD) comprises a broad spectrum of manifestation rangingfrom asymptomatic atherosclerosis to stable angina pectoris (SAP), acute coronarysyndrome (ACS), myocardial infarction (MI) and congestive heart failure (CHF). Themanagement of SAP has not been extensively studied in large randomised clinicaltrials.In Malaysia, these patients may be managed by cardiologists, physicians and primarycare doctors. The CPG on Management of SAP was developed to help guide cliniciansin the management of this group of patients.
- Pulmonary arterial hypertension (PAH) is defined as a group of diseases characterised by a progressive increase of pulmonary vascular resistance (PVR) leading to right ventricular failure and premature death. Untreated, it is a potentially devastating disease.
- Atrial fibrillation (AF) is an atrial tachyarrhythmia characterized by uncoordinated atrial activation with consequent deterioration of atrial mechanical function.
- In 2009, cardiovascular disease (CVD) was the leading cause of death in both men and women1. CVD includes coronary heart disease (CHD), cerebrovascular disease and peripheral arterial disease. CHD is a spectrum ranging from stable angina to acute coronary syndromes (ACS)
- Cardiovascular Disease (CVD) is one of the main causes of mortality and morbidity in Malaysia. The estimated incidence of Acute Coronary Syndrome (ACS) is 141 per 100,000 population per year, and the in-patient mortality rate is approximately 7%.
- Clinical Practice Guidelines for PCI Treatment of ischemic heart disease has evolved rapidly over the last decade. In Malaysia, we have now published Guidelines on treatment of various aspects of heart disease, including hypertension and myocardial infarction.